SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/335561"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/335561" > Impact of BMI in Pa...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005921naa a2200937 4500
001oai:gup.ub.gu.se/335561
003SwePub
008240528s2023 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:237556775
009oai:prod.swepub.kib.ki.se:154966939
0247 a https://gup.ub.gu.se/publication/3355612 URI
0247 a https://doi.org/10.1200/JCO.23.001262 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:2375567752 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1549669392 URI
040 a (SwePub)gud (SwePub)kid (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Pfeiler, Georg4 aut
2451 0a Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
264 1c 2023
520 a PURPOSEBMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of the global randomized PALLAS trial investigates the impact of BMI on the side-effect profile, treatment adherence, and efficacy of palbociclib.METHODSPatients were categorized at baseline according to WHO BMI categories. Neutropenia rates were assessed with univariable and multivariable logistic regression. Time to early discontinuation of palbociclib was analyzed with Fine and Gray competing risk models. Unstratified Cox models were used to investigate the association between BMI category and time to invasive disease-free survival (iDFS). 95% CIs were derived.RESULTSOf 5,698 patients included in this analysis, 68 (1.2%) were underweight, 2,082 (36.5%) normal weight, 1,818 (31.9%) overweight, and 1,730 (30.4%) obese at baseline. In the palbociclib arm, higher BMI was associated with a significant decrease in neutropenia (unadjusted odds ratio for 1-unit change, 0.93; 95% CI, 0.91 to 0.94; adjusted for age, race ethnicity, region, chemotherapy use, and Eastern Cooperative Oncology Group at baseline, 0.93; 95% CI, 0.92 to 0.95). This translated into a significant decrease in treatment discontinuation rate with higher BMI (adjusted hazard ratio [HR] for 10-unit change, 0.75; 95% CI, 0.67 to 0.83). There was no significant improvement in iDFS with the addition of palbociclib to ET in any weight category (normal weight HR, 0.84; 95% CI, 0.63 to 1.12; overweight HR, 1.10; 95% CI, 0.82 to 1.49; and obese HR, 0.95; 95% CI, 0.69 to 1.30) in this analysis early in follow-up (31 months).CONCLUSIONThis preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. Additional long-term follow-up will further evaluate whether BMI ultimately affects outcome. This preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Hlauschek, Dominik4 aut
7001 a Mayer, Erica L.4 aut
7001 a Deutschmann, Christine4 aut
7001 a Kacerovsky-Strobl, Stephanie4 aut
7001 a Martin, Miguel4 aut
7001 a Meisel, Jane Lowe4 aut
7001 a Zdenkowski, Nicholas4 aut
7001 a Loibl, Sibylle4 aut
7001 a Balic, Marija4 aut
7001 a Park, Haeseong4 aut
7001 a Prat, Aleix4 aut
7001 a Isaacs, Claudine4 aut
7001 a Bajetta, Emilio4 aut
7001 a Balko, Justin M.4 aut
7001 a Bellet-Ezquerra, Merixtell4 aut
7001 a Bliss, Judith4 aut
7001 a Burstein, Harold4 aut
7001 a Cardoso, Fatima4 aut
7001 a Fohler, Hannes4 aut
7001 a Foukakis, Theodorosu Karolinska Institutet4 aut
7001 a Gelmon, Karen A.4 aut
7001 a Goetz, Matthew4 aut
7001 a Haddad, Tufia C.4 aut
7001 a Iwata, Hiroji4 aut
7001 a Jassem, Jacek4 aut
7001 a Lee, Soo-Chin4 aut
7001 a Linderholm, Barbro,d 1959u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xlibar
7001 a Los, Maartje4 aut
7001 a Mamounas, Eleftherios P.4 aut
7001 a Miller, Kathy D.4 aut
7001 a Morris, Patrick G.4 aut
7001 a Munzone, Elisabetta4 aut
7001 a Gal-Yam, Einav Nili4 aut
7001 a Ring, Alistair4 aut
7001 a Shepherd, Lois4 aut
7001 a Singer, Christian4 aut
7001 a Thomssen, Christoph4 aut
7001 a Tseng, Ling-Ming4 aut
7001 a Valagussa, Pinuccia4 aut
7001 a Winer, Eric P.4 aut
7001 a Wolff, Antonio C.4 aut
7001 a Zoppoli, Gabriele4 aut
7001 a Machacek-Link, Jana4 aut
7001 a Schurmans, Celine4 aut
7001 a Huang, Xin4 aut
7001 a Gauthier, Eric4 aut
7001 a Fesl, Christian4 aut
7001 a Dueck, Amylou C.4 aut
7001 a DeMichele, Angela4 aut
7001 a Gnant, Michael4 aut
7102 a Karolinska Institutetb Institutionen för kliniska vetenskaper, Avdelningen för onkologi4 org
7730 t JOURNAL OF CLINICAL ONCOLOGYg 41:33q 41:33x 0732-183Xx 1527-7755
8564 8u https://gup.ub.gu.se/publication/335561
8564 8u https://doi.org/10.1200/JCO.23.00126
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:237556775
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:154966939

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy